Previous 10 | Next 10 |
Ayala Pharmaceuticals ([[AYLA]] +5.0%) entered into a definitive agreement for the sale of its equity securities in a private placement to institutional investors, including Redmile Group and SIO Capital Management.Ayala plans to sell 1.67M units at $15/unit; each unit consists of one share a...
Funding Extends Cash Runway through Multiple Expected Value Drivers Into 2023 Funds Expected to Support the Recently Announced Accelerated Development of AL102 for the Treatment of Desmoid Tumors into Pivotal Phase 2/3 Study REHOVOT, Israel and WILMINGTON, Del., Feb. 19, 202...
Gainers: ESSA Pharma (EPIX) +47%. Ayala Pharmaceuticals (AYLA) +45%. GenMark Diagnostics (GNMK) +27%. ADiTx Therapeutics (ADTX) +27%. Celsion (CLSN) +26%.Losers: Tilray (TLRY) -39%. Anchiano Therapeutics (ANCN) -35%. Zynerba Pharmaceuticals (ZYNE) -28%. Pulmatrix (PULM) -26%. Aphria (APHA) -2...
Gainers: RCM Technologies (RCMT) +85%.Ayala Pharmaceuticals (AYLA) +60%.ESSA Pharma (EPIX) +45%.GenMark Diagnostics (GNMK) +29%.Castor Maritime (CTRM) +28%.Borqs Technologies (BRQS) +26%.SOS Limited (SOS) +25%.Lyra Therapeutics (LYRA) +25%.Inpixon (INPX) +25%.Quotient Technology (QUOT) +...
Ayala Pharmaceuticals ([[AYLA]] -0.7%) has dosed the first patient in the Phase 2 TENACITY trial evaluating AL101, for the treatment of patients with Notch-activated recurrent or metastatic (R/M) triple negative breast cancer ((TNBC)).The study is designed to evaluate the efficacy and sa...
REHOVOT, Israel and WILMINGTON, Del., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announce...
REHOVOT, Israel and WILMINGTON, Del., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in g...
REHOVOT, Israel and WILMINGTON, Del., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in g...
Announcing the completion of the end-of-Phase 1 meeting with the FDA, Ayala Pharmaceuticals ([[AYLA]] -6.6%) says the regulator has granted the company to proceed with the Phase 2/3 pivotal study for AL102 in adult and adolescent patients with desmoid tumors.The study for the select...
- FDA Agreement from End-of-Phase 1 Meeting to Advance to Potential Registrational Study - - Pivotal Trial Expected to Initiate in 1H21 - REHOVOT, Israel & WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-sta...
News, Short Squeeze, Breakout and More Instantly...
Ayala Pharmaceuticals Inc. Company Name:
AYLA Stock Symbol:
NASDAQ Market:
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Societ...
Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily Enrollment in Phase 3 continuing as planned REHOVOT, Israel & MONMOUTH JUNCTION, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmace...